Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 5
1984 3
1985 1
1986 3
1987 8
1988 9
1989 9
1990 9
1991 15
1992 6
1993 12
1994 4
1995 5
1996 7
1997 12
1998 12
1999 5
2000 3
2001 8
2002 5
2003 6
2004 3
2005 10
2006 7
2007 4
2008 7
2009 5
2010 3
2011 3
2012 1
2013 3
2014 4
2015 1
2016 2
2017 3
2018 2
2019 5
2021 2
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Nilutamide-induced neutropenia.
Eaton VS, Blackmore TK. Eaton VS, et al. BJU Int. 2001 Nov;88(7):801-2. doi: 10.1046/j.1464-4096.2001.00905.x. BJU Int. 2001. PMID: 11890258 No abstract available.
Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ, Holdsworth MT. Dole EJ, et al. Ann Pharmacother. 1997 Jan;31(1):65-75. doi: 10.1177/106002809703100112. Ann Pharmacother. 1997. PMID: 8997470 Review.
DATA SOURCES: MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide, bicalutamide, and flutamide alone, and either nilutamide or androgen antagonists in combination with prostatic neoplasms. ...No co …
DATA SOURCES: MEDLINE (1980-1995) and CANCERLIT (1991-1995) were searched for English-language publications using the terms nilutamide …
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ. Du Plessis DJ. Urology. 1991;37(2 Suppl):20-4. doi: 10.1016/0090-4295(91)80097-q. Urology. 1991. PMID: 1992599 Review.
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), significantly reduced bone pain, and fewer patients experienced worsening pain than in the control group. ...Nilutamide was generally well t …
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), signifi …
Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W, Tanguay S, Aprikian AG. Kassouf W, et al. J Urol. 2003 May;169(5):1742-4. doi: 10.1097/01.ju.0000057795.97626.66. J Urol. 2003. PMID: 12686822
During followup 6 of the 28 patients died 1 of whom was a nilutamide responder. No patient died while on nilutamide. CONCLUSIONS: Nilutamide can achieve a significant sustained PSA response with a favorable toxicity profile. Patients with a previous antiandro …
During followup 6 of the 28 patients died 1 of whom was a nilutamide responder. No patient died while on nilutamide. CONCLUSIO …
Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
Harris MG, Coleman SG, Faulds D, Chrisp P. Harris MG, et al. Drugs Aging. 1993 Jan-Feb;3(1):9-25. doi: 10.2165/00002512-199303010-00002. Drugs Aging. 1993. PMID: 8453188 Review.
Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. ...Nilutamide has a long half-life which permits once-daily administration. ...
Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid r …
Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes.
Horsmans Y, Lannes D, Larrey D, Tinel M, Letteron P, Loeper J, Pessayre D. Horsmans Y, et al. Xenobiotica. 1991 Dec;21(12):1559-70. doi: 10.3109/00498259109044405. Xenobiotica. 1991. PMID: 1785203
Nilutamide (100 microM) markedly inhibited mephenytoin 4-hydroxylase activity in human liver microsomes. ...It is suggested that inhibition is likely to occur in vivo in humans receiving therapeutic doses of nilutamide....
Nilutamide (100 microM) markedly inhibited mephenytoin 4-hydroxylase activity in human liver microsomes. ...It is suggested that inhi …
Antiandrogenic drugs.
McLeod DG. McLeod DG. Cancer. 1993 Feb 1;71(3 Suppl):1046-9. doi: 10.1002/1097-0142(19930201)71:3+<1046::aid-cncr2820711424>3.0.co;2-m. Cancer. 1993. PMID: 8428326 Review.
Nonsteroidal antiandrogenic agents (flutamide, Casodex [ICI Pharmaceuticals, England], and nilutamide) block cellular binding of androgens only, and there is no reduction of testosterone levels. ...
Nonsteroidal antiandrogenic agents (flutamide, Casodex [ICI Pharmaceuticals, England], and nilutamide) block cellular binding of andr …
Nilutamide pneumonitis: a report on eight patients.
Pfitzenmeyer P, Foucher P, Piard F, Coudert B, Braud ML, Gabez P, Lacroix S, Mabille JP, Camus P. Pfitzenmeyer P, et al. Thorax. 1992 Aug;47(8):622-7. doi: 10.1136/thx.47.8.622. Thorax. 1992. PMID: 1412120 Free PMC article.
Seven had received nilutamide at the recommended dosage of 150 mg/day, and one had received twice that amount. ...The outcome was favourable in all patients after they had stopped nilutamide only (five patients), with corticosteroids (two patients) or a simple reduc …
Seven had received nilutamide at the recommended dosage of 150 mg/day, and one had received twice that amount. ...The outcome was fav …
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al. Janknegt RA, et al. J Urol. 1993 Jan;149(1):77-82; discussion 83. doi: 10.1016/s0022-5347(17)36003-2. J Urol. 1993. PMID: 7678043 Clinical Trial.
Progression-free survival was significantly longer in the nilutamide group (median time to progression 20.8 months on nilutamide and 14.9 months on placebo, p = 0.005). Median time to death from prostatic cancer was 30.0 months in the placebo group and 37 months in …
Progression-free survival was significantly longer in the nilutamide group (median time to progression 20.8 months on nilutamide …
209 results